HRP20240161T1 - Inhibitor atr i njegova primjena - Google Patents
Inhibitor atr i njegova primjena Download PDFInfo
- Publication number
- HRP20240161T1 HRP20240161T1 HRP20240161TT HRP20240161T HRP20240161T1 HR P20240161 T1 HRP20240161 T1 HR P20240161T1 HR P20240161T T HRP20240161T T HR P20240161TT HR P20240161 T HRP20240161 T HR P20240161T HR P20240161 T1 HRP20240161 T1 HR P20240161T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- group
- independently selected
- tautomer
- pharmaceutically acceptable
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- YOUKLMVEOLMTPU-CYBMUJFWSA-N (3R)-3-methyl-4-[2-(1H-pyrrolo[2,3-b]pyridin-4-yl)-6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-4-yl]morpholine Chemical compound N1C=CC=2C1=NC=CC=2C1=NC(=CC(=N1)N1[C@@H](COCC1)C)C=1C=NC(=CC=1)C(F)(F)F YOUKLMVEOLMTPU-CYBMUJFWSA-N 0.000 claims 1
- ZTPGLEZUDPBVFN-CQSZACIVSA-N (3R)-3-methyl-4-[6-pyridin-3-yl-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]morpholine Chemical compound C[C@H]1N(CCOC1)C1=NC(=NC(=C1)C=1C=NC=CC=1)C1=C2C(=NC=C1)NC=C2 ZTPGLEZUDPBVFN-CQSZACIVSA-N 0.000 claims 1
- GCPKEPSTJSFNGU-CYBMUJFWSA-N 5-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]pyridin-2-amine Chemical compound C[C@@H]1COCCN1C1=CC(=NC(=N1)C1=C2C(=NC=C1)NC=C2)C=1C=CC(=NC=1)N GCPKEPSTJSFNGU-CYBMUJFWSA-N 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Spoj formule (I), ili njegov tautomer ili farmaceutski prihvatljiva sol,
[image]
pri čemu
n je 1, 2, 3 ili 4;
Z1, Z2, i Z3 su svaki neovisno izabrani iz grupe koja se sastoji od CH i N, i najmanje jedan od Z1, Z2 i Z3 je N;
T1 i T2 su svaki neovisno izabrani iz grupe koja se sastoji od C(R2) i N;
prsten A je izabran iz grupe koja se sastoji od pirazolila, izoksazolila, oksazolila, imidazolila, 1,2,3-triazolila, 1,2,4-triazolila i piridila;
R1 je svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, C1-6 alkila, C1-6 alkoksi i C3-6 cikloalkila, pri čemu su C1-6 alkil, C1-6 alkoksi i C3-6 cikloalkil izborno supstituirani sa 1, 2 ili 3 R;
R2 je svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, COOH i C1-3 alkila, pri čemu je C1-3 alkil izborno supstituiran sa 1, 2 ili 3 R;
R je svaki neovisno izabran iz grupe koja se sastoji od F, Cl, Br, I, OH, NH2, C1-3 alkila i C1-3 alkoksi, pri čemu su C1-3 alkil i C1-3 alkoksi izborno supstituirani sa 1, 2 ili 3 R';
R' je svaki neovisno izabran iz grupe koja se sastoji od F, Cl, Br, I, OH i NH2; pod uvjetom da spoj formule (I) nije:
(3R)-3-metil-4-[6-(piridin-3-il)-2-[1H-pirolo[2,3-b]piridin-4-il]pirimidin-4-il]morfolin,
(R)-4-(2-(1H-pirolo[2,3-b]piridin-4-il)-6-(6-(trifluorometil)piridin-3-il)pirimidin-4-il)-3- metilmorfolin, ili
(R)-5-(6-(3-metilmorfolino)-2-(1H-pirolo[2,3-b]piridin-4-il)pirimidin-4-il)piridin-2-amin.
2. Spoj formule (I) prema patentnom zahtjevu 1, ili njegov tautomer ili farmaceutski prihvatljiva sol,
[image]
pri čemu,
n je 1, 2, 3 ili 4;
Z1, Z2 i Z3 su svaki neovisno izabrani iz grupe koja se sastoji od CH i N, i najmanje jedan od Z1, Z2 i Z3 je N;
T1 i T2 su svaki neovisno izabrani iz grupe koja se sastoji od C(R2) i N;
R2 je svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, COOH i C1-3 alkila, pri čemu je C1-3 alkil izborno supstituiran sa 1, 2 ili 3 R;
R je svaki neovisno izabran iz grupe koja se sastoji od F, Cl, Br, I, OH, NH2, C1-3 alkila i C1-3 alkoksi, pri čemu su C1-3 alkil i C1-3 alkoksi izborno supstituirani sa 1, 2 ili 3 R';
R' je svaki neovisno izabran iz grupe koja se sastoji od F, Cl, Br, I, OH i NH2; i
(i) prsten A je izabran iz grupe koja se sastoji od pirazolila, izoksazolila, oksazolila, imidazolila, 1,2,3-triazolila i 1,2,4-triazolila; i
R1 je svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, C1-6 alkila, C1-6 alkoksi i C3-6 cikloalkila, pri čemu su C1-6 alkil, C1-6 alkoksi i C3-6 cikloalkil izborno supstituirani sa 1, 2 ili 3 R;
ili
(ii) strukturna jedinica
[image]
je izabrana iz grupe koja se sastoji od
[image]
i
[image]
3. Spoj prema patentnom zahtjevu 1 ili 2, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je R svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, CH3, Et i -O-CH3.
4. Spoj prema bilo kojem od patentnih zahtjeva 1-3, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je R1 svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, C1-3 alkila, C1-3 alkoksi i ciklopropila, pri čemu su C1-3 alkil, C1-3 alkoksi i ciklopropil izborno supstituirani sa 1, 2 ili 3 R.
5. Spoj prema patentnom zahtjevu 4, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je R1 svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, CH3, CH2F, CHF2, CF3, Et, -CH2OH, -O-CH3,
[image]
i
[image]
6. Spoj prema bilo kojem od patentnih zahtjeva 1-5, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je R2 svaki neovisno izabran iz grupe koja se sastoji od H, F, Cl, Br, I, OH, NH2, COOH, CH3, Et i -CH2-OH.
7. Spoj prema bilo kojem od patentnih zahtjeva 1-6, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je prsten A izabran iz grupe koja se sastoji od
[image]
[image]
i
[image]
8. Spoj prema bilo kojem od patentnih zahtjeva 1-7, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je strukturna jedinica
[image]
izabrana iz grupe koja se sastoji od
[image]
[image]
i
[image]
9. Spoj prema bilo kojem od patentnih zahtjeva 1-8, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je strukturna jedinica
[image]
izabrana iz grupe koja se sastoji od
[image]
[image]
[image]
i
[image]
10. Spoj prema bilo kojem od patentnih zahtjeva 1-9, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je strukturna jedinica
[image]
izabrana iz grupe koja se sastoji od
[image]
i
[image]
11. Spoj prema bilo kojem od patentnih zahtjeva 1-10, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je strukturna jedinica
[image]
izabrana iz grupe koja se sastoji od
[image]
i
[image]
12. Spoj prema bilo kojem od patentnih zahtjeva 1-8, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je spoj izabran od
[image]
[image]
i
[image]
pri čemu
T1 i T2 su svaki neovisno izabrani iz grupe koja se sastoji od C(R2) i N;
Z1, Z2 i Z3 su definirani kao u patentnom zahtjevu 1 ili 2;
R1 je definiran kao u bilo kojem od patentnih zahtjeva 1, 2, 3, 4 ili 5;
R2 je definiran kao u patentnom zahtjevu 1 ili 6.
13. Spoj prema patentnom zahtjevu 12, ili njegov tautomer ili farmaceutski prihvatljiva sol, pri čemu je spoj izabran od
[image]
[image]
[image]
[image]
[image]
i
[image]
pri čemu
Z1, Z2 i Z3 su definirani kao u patentnom zahtjevu 1 ili 2;
R1 je definiran kao u bilo kojem od patentnih zahtjeva 1, 2, 3, 4 ili 5;
R2 je definiran kao u patentnom zahtjevu 1 ili 6.
14. Spoj ili njegov tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1-13, izabran od
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
15. Spoj prema bilo kojem od patentnih zahtjeva 1-14, ili njegov tautomer ili farmaceutski prihvatljiva sol, za uporabu u liječenju solidnog tumora ili hematološkog tumora.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810124494 | 2018-02-07 | ||
| CN201811361512 | 2018-11-15 | ||
| EP19750376.6A EP3753937B1 (en) | 2018-02-07 | 2019-02-02 | Atr inhibitor and application thereof |
| PCT/CN2019/074578 WO2019154365A1 (zh) | 2018-02-07 | 2019-02-02 | 一种atr抑制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240161T1 true HRP20240161T1 (hr) | 2024-04-12 |
Family
ID=67548753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240161TT HRP20240161T1 (hr) | 2018-02-07 | 2019-02-02 | Inhibitor atr i njegova primjena |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11434232B2 (hr) |
| EP (1) | EP3753937B1 (hr) |
| JP (1) | JP7290651B2 (hr) |
| CN (1) | CN111712499B (hr) |
| AU (1) | AU2019217388C1 (hr) |
| BR (1) | BR112020016020A8 (hr) |
| CA (1) | CA3090330A1 (hr) |
| DK (1) | DK3753937T3 (hr) |
| ES (1) | ES2970074T3 (hr) |
| FI (1) | FI3753937T3 (hr) |
| HR (1) | HRP20240161T1 (hr) |
| IL (1) | IL276489B1 (hr) |
| LT (1) | LT3753937T (hr) |
| PL (1) | PL3753937T3 (hr) |
| PT (1) | PT3753937T (hr) |
| RS (1) | RS65147B1 (hr) |
| SG (1) | SG11202007485PA (hr) |
| SI (1) | SI3753937T1 (hr) |
| WO (1) | WO2019154365A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220378799A1 (en) * | 2019-06-06 | 2022-12-01 | Beijing Tide Pharmaceutical Co., Ltd. | 2, 4, 6-tri-substituted pyrimidine compound as atr kinase inhibitor |
| JP2022543856A (ja) * | 2019-08-06 | 2022-10-14 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ａｔｒ阻害剤の結晶形及びその使用 |
| US20230212160A1 (en) * | 2020-05-20 | 2023-07-06 | Beijing Tide Pharmaceutical Co., Ltd. | 2,4,6-tri-substituted pyrimidine compounds as atr kinase inhibitors |
| WO2021238999A1 (zh) * | 2020-05-29 | 2021-12-02 | 深圳市瓴方生物医药科技有限公司 | 氟代吡咯并吡啶类化合物及其应用 |
| CN116635082A (zh) * | 2020-06-24 | 2023-08-22 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atr抑制剂的组合 |
| TW202216701A (zh) * | 2020-07-03 | 2022-05-01 | 香港商德琪研發有限公司 | Atr抑制劑及其用途 |
| CN116178366A (zh) * | 2021-11-26 | 2023-05-30 | 深圳市瓴方生物医药科技有限公司 | 氟代吡啶并吡咯类化合物的晶型及其制备方法 |
| WO2023131234A1 (en) * | 2022-01-06 | 2023-07-13 | Shanghai Antengene Corporation Limited | Crystalline forms of an atr inhibitor |
| WO2023215133A1 (en) * | 2022-05-02 | 2023-11-09 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009093981A1 (en) * | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Triazine compounds as kinase inhibitors |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| UY32351A (es) | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| US9481670B2 (en) | 2011-01-25 | 2016-11-01 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
| AR095443A1 (es) * | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| WO2019050889A1 (en) * | 2017-09-08 | 2019-03-14 | Bluevalley Pharmaceutical Llc | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS |
-
2019
- 2019-02-02 PL PL19750376.6T patent/PL3753937T3/pl unknown
- 2019-02-02 RS RS20240129A patent/RS65147B1/sr unknown
- 2019-02-02 US US16/968,429 patent/US11434232B2/en active Active
- 2019-02-02 BR BR112020016020A patent/BR112020016020A8/pt unknown
- 2019-02-02 CN CN201980012249.5A patent/CN111712499B/zh active Active
- 2019-02-02 IL IL276489A patent/IL276489B1/en unknown
- 2019-02-02 HR HRP20240161TT patent/HRP20240161T1/hr unknown
- 2019-02-02 AU AU2019217388A patent/AU2019217388C1/en active Active
- 2019-02-02 ES ES19750376T patent/ES2970074T3/es active Active
- 2019-02-02 SI SI201930708T patent/SI3753937T1/sl unknown
- 2019-02-02 DK DK19750376.6T patent/DK3753937T3/da active
- 2019-02-02 WO PCT/CN2019/074578 patent/WO2019154365A1/zh active Application Filing
- 2019-02-02 PT PT197503766T patent/PT3753937T/pt unknown
- 2019-02-02 EP EP19750376.6A patent/EP3753937B1/en active Active
- 2019-02-02 FI FIEP19750376.6T patent/FI3753937T3/fi active
- 2019-02-02 LT LTEPPCT/CN2019/074578T patent/LT3753937T/lt unknown
- 2019-02-02 JP JP2020542631A patent/JP7290651B2/ja active Active
- 2019-02-02 CA CA3090330A patent/CA3090330A1/en active Pending
- 2019-02-02 SG SG11202007485PA patent/SG11202007485PA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3753937B1 (en) | 2024-01-10 |
| FI3753937T3 (fi) | 2024-01-31 |
| US20200399260A1 (en) | 2020-12-24 |
| SG11202007485PA (en) | 2020-09-29 |
| AU2019217388C1 (en) | 2024-03-07 |
| EP3753937A4 (en) | 2021-07-07 |
| DK3753937T3 (da) | 2024-02-12 |
| EP3753937A1 (en) | 2020-12-23 |
| BR112020016020A8 (pt) | 2023-04-25 |
| PT3753937T (pt) | 2024-02-06 |
| JP7290651B2 (ja) | 2023-06-13 |
| IL276489B1 (en) | 2024-05-01 |
| WO2019154365A1 (zh) | 2019-08-15 |
| CN111712499B (zh) | 2023-06-02 |
| IL276489A (en) | 2020-09-30 |
| JP2021512908A (ja) | 2021-05-20 |
| SI3753937T1 (sl) | 2024-03-29 |
| AU2019217388A1 (en) | 2020-09-03 |
| CA3090330A1 (en) | 2019-08-15 |
| US11434232B2 (en) | 2022-09-06 |
| AU2019217388B2 (en) | 2023-11-09 |
| RS65147B1 (sr) | 2024-02-29 |
| PL3753937T3 (pl) | 2024-04-02 |
| BR112020016020A2 (pt) | 2020-12-08 |
| LT3753937T (lt) | 2024-02-26 |
| CN111712499A (zh) | 2020-09-25 |
| ES2970074T3 (es) | 2024-05-24 |
| RU2020128324A (ru) | 2022-03-09 |
| RU2020128324A3 (hr) | 2022-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240161T1 (hr) | Inhibitor atr i njegova primjena | |
| HRP20180382T1 (hr) | Inhibitori protein kinaze | |
| HRP20220255T1 (hr) | Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka | |
| HRP20210813T1 (hr) | Piridinonpiridinilni spojevi supstituirani s metil/fluorpiridinilmetoksi i piridinonpiridinilni spojevi supstituirani s fluorpirimidinilmetoksi | |
| JP2016525075A5 (hr) | ||
| HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
| HRP20161482T1 (hr) | Derivati tienopiridona korisni kao aktivatori ampk | |
| JP2015531366A5 (hr) | ||
| HRP20161547T1 (hr) | Derivati 5-fluor-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku skupinu | |
| RU2015139590A (ru) | ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ | |
| JP2015537015A5 (hr) | ||
| SI3004090T1 (en) | Chemical compounds | |
| RS54339B1 (en) | NEW ANTIMALARIAN AGENTS | |
| JP2017537949A5 (hr) | ||
| JP2013523710A5 (hr) | ||
| HRP20151399T1 (hr) | Kinazni inhibitor koji regulira signalni put apoptoze | |
| SI2978752T1 (en) | 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD | |
| HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| JP2016522232A5 (hr) | ||
| HRP20211957T1 (hr) | Analozi 1,4-disupstituiranog piridazina i postupci za liječenje stanja povezanih s nedostatkom smn | |
| JP2016521710A5 (hr) | ||
| NZ609955A (en) | Sgc stimulators | |
| RS54415B1 (en) | BENZAMIDE SUBSTITUTED DERIVATIVES | |
| RU2010125220A (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| HRP20210320T1 (hr) | Spojevi heteroarila za liječenje oftalmičkih bolesti |